Rare Infection in Transplant Recipients Linked to Donors
By LabMedica International staff writers Posted on 01 Jun 2017 |

Image: Mycoplasma hominis, the bacteria responsible for a rare infection in transplant recipients (Photo courtesy of the Mayo Clinic).
The way in which heart and lung transplant recipients acquired a specific species of bacteria, Mycoplasma hominis, had been previously undefined, and the bacterium was difficult to test for and detect. Originally, this bacterium was considered to reside exclusively in, and be a potential pathogen of the area of the reproductive and urinary organs.
M. hominis resists most antibiotics, and the three antibiotic treatment recommendations for these infections are neither standard for post-transplant recipient care nor are they standard in therapy regimens for surgical site infections. Heart and lung transplant recipient infection caused by M. hominis may present with, surgical site infection and mediastinitis, which is an inflammation of tissue in mid-chest.
Scientists at the Mayo Clinic investigated lung and heart-lung transplants between 1998 and July 2015 at the Mayo Clinic. Seven previously unreported cases of transplant recipients with M. hominis infection were discovered. In each case, pre-transplant sputum cultures had tested negative for M. hominis. A literature review since 1950 found 15 cases of M. hominis infection in lung, heart or heart-lung transplant recipients. The way the bacteria spread remained uncertain. Given its normal residence in the genitourinary tract, some speculated that infection arose from urinary catheter placement during the transplant surgery.
Bronchoalveolar lavage samples were submitted for detecting organisms commonly found in immunocompromised hosts undergoing clinically indicated bronchoscopy were tested for M. hominis DNA. DNA was extracted on the MagNA Pure LC instrument using the MagNA Pure total nucleic acid isolation kit. Common testing methods have proven insufficient in identifying the bacteria, but the use of polymerase chain reaction offered a more time-sensitive and specific test for the bacteria. With this method, the scientists were able to focus in on a certain portion of DNA and then create multiple copies to amplify the segment. Polymerase chain reaction detection reduces the time to detect M. hominis to a few hours, compared to the two to five days needed for a culture media test.
Mark E. Wylam, MD, the lead investigator said, “These findings could affect how we approach the evaluation of organ donors. If potential transmission of these harmful bacteria can be identified and addressed, the recipient will face a decreased risk of infection and its serious complications. This study shows us that surveillance of both donor and recipient are important in recognizing M. hominis and the infection it can cause.” The study was published in the May 2017 issue of the journal EbioMedicine.
M. hominis resists most antibiotics, and the three antibiotic treatment recommendations for these infections are neither standard for post-transplant recipient care nor are they standard in therapy regimens for surgical site infections. Heart and lung transplant recipient infection caused by M. hominis may present with, surgical site infection and mediastinitis, which is an inflammation of tissue in mid-chest.
Scientists at the Mayo Clinic investigated lung and heart-lung transplants between 1998 and July 2015 at the Mayo Clinic. Seven previously unreported cases of transplant recipients with M. hominis infection were discovered. In each case, pre-transplant sputum cultures had tested negative for M. hominis. A literature review since 1950 found 15 cases of M. hominis infection in lung, heart or heart-lung transplant recipients. The way the bacteria spread remained uncertain. Given its normal residence in the genitourinary tract, some speculated that infection arose from urinary catheter placement during the transplant surgery.
Bronchoalveolar lavage samples were submitted for detecting organisms commonly found in immunocompromised hosts undergoing clinically indicated bronchoscopy were tested for M. hominis DNA. DNA was extracted on the MagNA Pure LC instrument using the MagNA Pure total nucleic acid isolation kit. Common testing methods have proven insufficient in identifying the bacteria, but the use of polymerase chain reaction offered a more time-sensitive and specific test for the bacteria. With this method, the scientists were able to focus in on a certain portion of DNA and then create multiple copies to amplify the segment. Polymerase chain reaction detection reduces the time to detect M. hominis to a few hours, compared to the two to five days needed for a culture media test.
Mark E. Wylam, MD, the lead investigator said, “These findings could affect how we approach the evaluation of organ donors. If potential transmission of these harmful bacteria can be identified and addressed, the recipient will face a decreased risk of infection and its serious complications. This study shows us that surveillance of both donor and recipient are important in recognizing M. hominis and the infection it can cause.” The study was published in the May 2017 issue of the journal EbioMedicine.
Latest Microbiology News
- Viral Load Tests Can Help Predict Mpox Severity
- Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
- Credit Card-Sized Test Boosts TB Detection in HIV Hotspots
- Fecal Metabolite Profiling Predicts Mortality in Critically Ill Patients
- Portable Molecular POC System Rules Out UTIs in Just 35 Minutes
- POC Lateral Flow Test Detects Deadly Fungal Infection Faster Than Existing Techniques
- Rapid Diagnostic Test Slashes Sepsis Mortality by 39%
- Blood Culture Assay Enhances Diagnostic Stewardship Through Targeted Panel Selection
- Real-Time Genome Sequencing Detects Dangerous Superbug Causing Hospital Infections
- Diagnostic Test Accurately Detects Colorectal Cancer by Identifying Microbial Signature in Gut Bacteria
- Rapid Bedside Test Predicts Sepsis with Over 90% Accuracy
- New Blood Test Detects Up to Five Infectious Diseases at POC
- Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
- New Test Diagnoses Bacterial Meningitis Quickly and Accurately
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Ultra-Sensitive Biosensor Based on Light and AI Enables Early Cancer Diagnosis
Cancer diagnosis is often delayed due to the difficulty in detecting early-stage cancer markers. In particular, the concentration of methylated DNA in the bloodstream during the early stages of cancer... Read moreIndustry
view channel
Quanterix Completes Acquisition of Akoya Biosciences
Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution... Read more
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more